Tirzepatide is a dual agonist peptide targeting both GLP-1 and GIP receptors, studied extensively in metabolic and endocrine research. It has been investigated for its effects on insulin signaling, glucagon modulation, and energy homeostasis through multi-receptor activation. Preclinical and clinical research models explore its influence on glucose regulation, appetite pathways, and hormonal signaling networks. Its dual incretin mechanism differentiates it from single-pathway analogs, contributing to interest in complex metabolic modulation. Structural engineering supports extended activity and receptor stability in controlled environments. Ongoing research continues to evaluate its signaling dynamics and pharmacological properties.